World IP Day: The big ideas shaping IP's fastest-moving fields

​
April 24, 2026

What's really driving the next wave of IP? To mark World IP Day, we asked the specialists leading EIP's five focus areas, Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share what's changing in their field and what's coming next.

What is one emerging client expectation or behaviour that you believe will redefine how we deliver UPC strategy over the next year?

Michael Nielsen, Partner, UK and European Patent Attorney, UPC Representative, Uniphy

As the UPC matures, clients increasingly expect their advisers to operate as a genuinely joined‑up team, rather than in silos. All but the most straightforward cases require lawyers and patent attorneys working closely together, aligning technical and legal strategy for a case, as well as effective cross‑border coordination. EIP is already exceptionally well placed for this, with our long history of joined up work between litigators and patent attorneys and our excellent teams in Germany, the UK, and Sweden working together to achieve the best outcomes in complex cases. We will continue to strengthen our internal collaboration so that we can offer the highest quality UPC advice and representation to our clients.

From your perspective, how is the broader conversation around IP changing, and what opportunities does this create for how we communicate EIP’s value to the world?

Andrew Thompson, Partner, UK and European Patent Attorney, UPC Representative, Ampliphy

There is a better appreciation of the role IP plays. More people in business understand that IP is not just a legal right, but a tool to help drive value. This sits perfectly with EIP's strategic approach to IP, and our expertise in high value and complex patent matters.

What is one strategic shift in how companies are using IP to drive business value that you think everyone should be paying attention to this World IP Day?

Gareth Probert, Partner, UK and European Patent Attorney, UPC Representative, Stratiphy

One shift is the growing IP awareness in life science start‑ups and scale‑ups compared to the past. These innovator companies have a more positive attitude to IP, recognising that a well-planned IP portfolio is essential in attracting future investment and deals, alongside with a transparent FTO position.

AI continues to accelerate across industries. What is one way you see technology fundamentally improving how we work with IP in the next 12 months?

Ben Maling, Partner, UK and European Patent Attorney, Codiphy

Patent drafting and prosecution are especially good use cases for generative AI, in that they involve reviewing and preparing large volumes of complicated text. In my view, the models have recently passed a threshold where they are capable enough to help us attorneys find meaningful efficiencies without sacrificing the quality of our work. To make the most of this, we'll need to be open to new ways of working and to reassess where we can add value. There is good reason to believe the counterintuitive notion that this new role in which we will find ourselves will in fact be more fulfilling and enjoyable than the one we've got used to.

What metric, trend, or insight about global innovation has surprised you most recently, and what does it tell us about where IP is headed?

Gemma Martynwood, Partner, UK and European Patent Attorney, UPC Representative, Quantiphy

There has been a huge push from governments to invest in quantum technologies, and the scale of recent UK government funding for quantum has been a (pleasant!) surprise. This positive funding climate should translate into a ramping up of IP generation within the quantum space. For quantum enterprises, a well thought-out IP strategy that considers not only their own activities but also those of their competitors will be ever more important as we start seeing more quantum tech being brought to market.

The big picture

Five areas, five perspectives, one clear message. IP is moving faster, working harder and mattering more than ever. Whether it's AI reshaping how patents are drafted, start-ups building IP into their growth story, or governments fuelling the next quantum leap, the opportunities ahead are considerable. EIP will keep helping clients turn them into lasting value.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​